Gilead Science Inc.'s U.S. pricing of its HIV prevention drug, Truvada (emtricitabine/tenofovir disoproxil fumarate), led to company Chairman and CEO Daniel O'Day getting the sole invite to testify in a hearing before the House Oversight and Reform Committee Thursday.